
LIB Therapeutics Announces FDA Acceptance of Lerodalcibep BLA for LDL-C Reduction
LIB Therapeutics Announces FDA Acceptance of Lerodalcibep BLA for LDL-C Reduction LIB Therapeutics Inc., a late-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted…